# If Daiichi Sankyo moves, who benefits? How far does the value-chain ripple reach?
Canonical: https://valuechain.wiki/daiichi-sankyo · Facet: ripple · Updated: 2026-07-12T04:47:15.227617+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Per the valuechain.wiki graph, Daiichi Sankyo is directly linked to 2 companies (1 supply, 1 revenue relationships) and reaches 3 companies within two hops; the links are backed by 6 dated sources, 4 of them primary filings (as of 2026-07-12).

Daiichi Sankyo operates across TSE, Oncology ADC, Enhertu world leader. It remained weak at -32.4% in 2025 and -0.2% in 2026. The demand side (avg +44.9%) is well ahead of the stock (-0.2%). Customer money has not fully worked its way down to this layer, which leaves catch-up room if propagation continues and a hardened gap if it stalls. Among connected nodes the furthest ahead is Merck & Co. (+44.9%) and the furthest behind is ALTEOGEN (-9.2%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. The company targets JPY 2.3 trillion in oncology revenue by 2030, expanding five DXd ADC medicines across more than 20 indications.

## Demand chain (leading)
- T1 Merck & Co. (https://valuechain.wiki/merck-co.md)
- T2 McKesson Corporation (https://valuechain.wiki/mckesson.md)
- T3 CVS Health (https://valuechain.wiki/cvs-health.md)
- T3 Walmart Inc (https://valuechain.wiki/walmart.md)

## Supply chain (benefiting)
- T1 ALTEOGEN (https://valuechain.wiki/alteogen.md)

---
Full node: https://valuechain.wiki/daiichi-sankyo.md · JSON: https://valuechain.wiki/daiichi-sankyo.json